Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (1051-1060 of 1,482) with videos related to

Pageof 149
Sort By:
Cancer|April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
The Journal of Clinical Investigation|January 6, 2022
Clonal hematopoiesis in sickle cell diseaseL Alexander Liggett, Liam D Cato, Joshua S Weinstock, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Cancers|April 13, 2023
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center ExperienceAdriana Trabal, Amber Gibson, Jiasen He, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
Leukemia|November 1, 2016
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trialsG Montalban-Bravo, X Huang, K Naqvi, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
The New England Journal of Medicine|June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid LeukemiaGail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Pageof 149

Showing results (1051-1060 of 1,482) with videos related to

Sort By:
Pageof 149
Cancer|April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
The Journal of Clinical Investigation|January 6, 2022
Clonal hematopoiesis in sickle cell diseaseL Alexander Liggett, Liam D Cato, Joshua S Weinstock, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Cancers|April 13, 2023
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center ExperienceAdriana Trabal, Amber Gibson, Jiasen He, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
Leukemia|November 1, 2016
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trialsG Montalban-Bravo, X Huang, K Naqvi, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
The New England Journal of Medicine|June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid LeukemiaGail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Pageof 149